new_0222_0459|ELYM|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0459|ELYM|1|Eliem Therapeutics Inc Total Current Assets (Quarterly) (USD)|Eliem Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Eliem Therapeutics Inc Inventories (Quarterly) (USD)|Eliem Therapeutics Inc Net PP&E (Quarterly) (USD)|Eliem Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Eliem Therapeutics Inc Total Liabilities (Quarterly) (USD)|Eliem Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Eliem Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Eliem Therapeutics Inc Total Deposits (Quarterly) (USD)|Eliem Therapeutics Inc Book Value (Quarterly) (USD)|Eliem Therapeutics Inc Retained Earnings (Quarterly) (USD)|Eliem Therapeutics Inc Treasury Stock (Quarterly) (USD)|Eliem Therapeutics Inc EV to Revenues|Eliem Therapeutics Inc EV to Earnings|Eliem Therapeutics Inc EV to Free Cash Flow|Eliem Therapeutics Inc EV to Assets (Quarterly)|Eliem Therapeutics Inc PS Ratio|Eliem Therapeutics Inc PE Ratio|Eliem Therapeutics Inc Price to Book Value|Eliem Therapeutics Inc PEG Ratio|Eliem Therapeutics Inc Debt to Equity Ratio|Eliem Therapeutics Inc Dividend Yield|Eliem Therapeutics Inc Shareholder Yield (TTM)|Eliem Therapeutics Inc Percent of Shares Outstanding Short|Eliem Therapeutics Inc Total Receivables (Quarterly) (USD)|Eliem Therapeutics Inc Total Payables (Quarterly) (USD)|Eliem Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Eliem Therapeutics Inc Return on Invested Capital|Eliem Therapeutics Inc Quality Ratio Score|Eliem Therapeutics Inc Momentum Score|Eliem Therapeutics Inc Beta (1Y)|Eliem Therapeutics Inc Sustainable Growth Rate (TTM)|Eliem Therapeutics Inc Institutional Investor Ownership Percentage|Eliem Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Eliem Therapeutics Inc Total Employees (Annual)|Eliem Therapeutics Inc EPS Diluted (Quarterly) (USD)|Eliem Therapeutics Inc SG&A Expense (Quarterly) (USD)|Eliem Therapeutics Inc Shares Outstanding|Eliem Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Eliem Therapeutics Inc Ordinary Shares Number (Quarterly)|Eliem Therapeutics Inc Payout Ratio|Eliem Therapeutics Inc Quick Ratio (Quarterly)|Eliem Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Eliem Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Eliem Therapeutics Inc Effective Tax Rate (TTM)|Eliem Therapeutics Inc Return on Equity|Eliem Therapeutics Inc Net Income (TTM) (USD)|Eliem Therapeutics Inc Revenue (TTM) (USD)|Eliem Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Eliem Therapeutics Inc Revenue (Quarterly) (USD)|Eliem Therapeutics Inc Gross Profit (Quarterly) (USD)|Eliem Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Eliem Therapeutics Inc Net Income (Quarterly) (USD)|Eliem Therapeutics Inc Net Interest Income (Quarterly) (USD)|Eliem Therapeutics Inc Price (USD)|Eliem Therapeutics Inc Total Return Price (USD)|Eliem Therapeutics Inc Enterprise Value (USD)|Eliem Therapeutics Inc 30-Day Average Daily Volume|Eliem Therapeutics Inc 1 Year Price Returns (Daily)|Eliem Therapeutics Inc Short Interest|Eliem Therapeutics Inc PE Ratio (Forward)|Eliem Therapeutics Inc PE Ratio (Forward 1y)|Eliem Therapeutics Inc PS Ratio (Forward)|Eliem Therapeutics Inc PS Ratio (Forward 1y)|Eliem Therapeutics Inc Quarterly EPS Estimates (USD)|Eliem Therapeutics Inc Quarterly Revenue Estimates (USD)|Eliem Therapeutics Inc Quarterly EPS Surprise|Eliem Therapeutics Inc Quarterly Revenue Surprise|Eliem Therapeutics Inc Quarterly Actual EPS (USD)|Eliem Therapeutics Inc Quarterly Actual Revenue (USD)|Eliem Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Eliem Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Eliem Therapeutics Inc Price Target (USD)|Eliem Therapeutics Inc Consensus Recommendation|Eliem Therapeutics Inc Price Target Num Estimates|Eliem Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Eliem Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Eliem Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Eliem Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Eliem Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Eliem Therapeutics Inc Land and Improvements (Quarterly) (USD)|Eliem Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Eliem Therapeutics Inc Other Properties (Quarterly) (USD)|Eliem Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0459|ELYM|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0459|ELYM|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0459|ELYM|5|91|91||||91|91|91||91|91||||1.4328358209||||1.4387755102|||1.4328358209||15.5454545455|91.5|91|91|||||||91.3333333333|46|91.3333333333|91.3333333333|18.8||91|||91.3333333333||||91|||||91.3333333333|91.3333333333||1.4328358209|1.4328358209|1.4328358209|1.42857142857||15.5454545455||||||91.5||||92|27.8|34.75|27.1666666667|20.375|27.1666666667|||91.3333333333||||||||
new_0222_0459|ELYM|6|3|3||||3|3|3||3|3||||134||||98|||134||11|2|3|3|||||||6|2|6|6|5||3|||6||||3|||||6|6||134|134|134|105||11||||||6||||1|5|4|6|8|6|||6||||||||
new_0222_0459|ELYM|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0459|ELYM|202003||||||||||||||||||||||||||||||||||11.6617||-0.2019|0.328||||||-0.2049|||||||||-1.916|-1.916|||||||||||||||||||||||||1.623||||||||
new_0222_0459|ELYM|202006||||||||||||||||||||||||||||||||||11.6617||-0.1786|0.248||||||-0.1379|||||||||-1.631|-1.631|||||||||||||||||||||||||1.36||||||||
new_0222_0459|ELYM|202009||||||||||||||||||||||||||||||||||11.6617||-0.2332|0.312||||||-0.1937|||||||||-2.258|-2.258|||||||||||||||||||||||||1.947||||||||
new_0222_0459|ELYM|202012|21.998|20.487||||3.063|3.063|||-24.983|-28.136|||||||||||||||1.293|46.552|||||||11.6617||-1.3545|1.537|||23.4582|||-1.2954||||-20.668|||||-14.863|-14.863|||||||||||||||||||||||||13.57||||||||
new_0222_0459|ELYM|202103|52.537|47.911||||4.07|4.07|||-43.182|-46.737||||||||||||||2.535|2.129|92.799|||||||11.6617||-1.69|2.218|||23.4582|||-1.6897||||-37.353|||||-18.601|-18.601|||||||||||||||||||||||||4.661||||||||
new_0222_0459|ELYM|202106|104.803|99.482||||5.713|5.713|||-50.845|-55.456||||-31.4041|||||||||0.9259|2.541|1.955|152.76||||||50.8509|23.4582|25|-0.463|2.914|26.3182||23.4582|||-0.3712||||-44.441|||||-8.719|-8.719||25.69|25.69|729.3916|||243688||||||||||||||||||5.793||||||||
new_0222_0459|ELYM|202109|158.632|146.018||||5.59|5.59|||176.661|-65.071||||-9.6133||||2.6665|||||2.0873|6.943|2.579|0.003|||||||15.5856|28|-0.7|3.394|26.1993||26.1993|||-0.6838|-83.144|||-51.798|||||-9.615|-9.615||17.98|17.98|325.0454|234874.5667||546860|||||||||||||33.3333|1|3|||5.989|||||||17.42|14.39
new_0222_0459|ELYM|202112|||||||||||||||-3.8962||||1.5723|||||3.004|||||||||||||||||||||||||||||||10.46|10.46|131.74|53185.7667||797704|||||||||||||33.3333|1|3||||||||||9.04|8.82
new_0222_0459|ELYM|202203||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
new_0222_0459|ELYM|202206||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
new_0222_0459|ELYM|202209||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
new_0222_0459|ELYM|202212||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||